ResMed Inc. (LON:0KW4)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 24.36B -12.6% |
| Revenue (ttm) | 4.32B +9.0% |
| Net Income | 1.20B +10.8% |
| EPS | 8.21 +12.4% |
| Shares Out | n/a |
| PE Ratio | 21.13 |
| Forward PE | 19.30 |
| Dividend | 1.96 (1.13%) |
| Ex-Dividend Date | Nov 12, 2026 |
| Volume | 451 |
| Open | 234.59 |
| Previous Close | 236.16 |
| Day's Range | 231.27 - 239.28 |
| 52-Week Range | 180.60 - 277.17 |
| Beta | 0.76 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About ResMed
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that me... [Read more]
Financial Performance
In fiscal year 2026, ResMed's revenue was $5.65 billion, an increase of 9.85% compared to the previous year's $5.15 billion. Earnings were $1.52 billion, an increase of 8.75%.
Financial numbers in USD Financial StatementsNews
Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
ResMed downgraded to Hold from Buy at Canaccord
Canaccord downgraded ResMed (RMD) to Hold from Buy with a price target of A$35.61, down from A$40.
ResMed price target raised to $288 from $262 at RBC Capital
RBC Capital raised the firm’s price target on ResMed (RMD) to $288 from $262 and keeps an Outperform rating on the shares. The company delivered a strong Q1, which beat…
ResMed price target raised to $277 from $267 at KeyBanc
KeyBanc raised the firm’s price target on ResMed (RMD) to $277 from $267 on higher estimates, while keeping an Overweight rating on the shares. The firm viewed ResMed’s Q1 release…
ResMed price target raised to $270 from $240 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on ResMed (RMD) to $270 from $240 and keeps an Outperform rating on the shares.
ResMed price target raised to $250 from $215 at Wells Fargo
Wells Fargo raised the firm’s price target on ResMed (RMD) to $250 from $215 and keeps an Equal Weight rating on the shares. The firm notes Q1 sales and EPS…
ResMed price target raised to $246 from $238 at Baird
Baird raised the firm’s price target on ResMed (RMD) to $246 from $238 and keeps a Neutral rating on the shares. The firm updated its model following positive Q1 results…
ResMed price target raised to $270 from $240 at Citi
Citi raised the firm’s price target on ResMed (RMD) to $270 from $240 and keeps a Neutral rating on the shares. The company reported a 9% core earnings beat in…
ResMed Earnings Call Transcript: Q1 2027
Q1 revenue grew 7% core constant currency and non-GAAP EPS rose 14%. FY27 guidance was reiterated, while inflation, France fleet renewal timing and Astral's planned exit shape the outlook.
ResMed Earnings release: Q1 2027
ResMed released its Q1 2027 earnings on October 29, 2026, summarizing the period's financial results.
ResMed Slides: Q1 2027
ResMed has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on October 29, 2026.
ResMed Earnings release: Q1 2027
ResMed released its Q1 2027 earnings on October 29, 2026, summarizing the period's financial results.
ResMed Quarterly report: Q1 2027
ResMed has published its Q1 2027 quarterly earnings report on October 29, 2026.
ResMed reports Q1 non-GAAP EPS $2.91, consensus $2.67
Reports Q1 revenue $1.4B, consensus $1.39B. “We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing…
ResMed sees FY27 non-GAAP EPS $12.00-$12.25, consensus $12.09
Sees FY27 revenue $5.75B-$5.85B, consensus $5.8B.
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. la...
ResMed price target raised to $240 from $235 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on ResMed (RMD) to $240 from $235 and keeps an Outperform rating on the shares. The firm adjusted targets in the…
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, O...
ResMed Proxy statement: Proxy filing
ResMed filed a proxy statement on October 1, 2026, providing details for shareholder voting and corporate governance matters.
ResMed Proxy statement: Proxy filing
ResMed filed a proxy statement on October 1, 2026, providing details for shareholder voting and corporate governance matters.
ResMed Slides: Stewardship presentation
ResMed has posted slides in relation to its latest quarterly earnings report, which was published on September 21, 2026.
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Setbacks for competitors have positioned ResMed to capture more market share.
ResMed Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Guidance was provided for 5%-7% revenue growth, with strong volume-driven performance and ongoing margin expansion through supply chain productivity. GLP-1s and consumer tech are fueling patient funnel growth, while acquisitions and digital engagement drive adherence. Portfolio management includes new M&A and sunsetting legacy products.